Nikša Drinković, Maja Beus, Rinea Barbir, Željko Debeljak, Blanka Tariba Lovaković, Nikolina Kalčec, Marija Ćurlin, Ana Bekavac, Dunja Gorup, Ivan Mamić, Dario Mandić, Vedran Micek, Petra Turčić, Nazende Günday-Türeli, Emre Türeli, Ivana Vinković Vrček
Nanotechnology has the potential to provide formulations of antitumor agents with increased selectivity towards cancer tissue thereby decreasing systemic toxicity. This in vivo study evaluated the potential of novel nanoformulation based on poly(lactic- co -glycolic acid) (PLGA) to reduce the cardiotoxic potential of doxorubicin (DOX). In vivo toxicity of PLGADOX was compared with clinically approved non-PEGylated, liposomal nanoformulation of DOX (LipoDOX) and conventional DOX form (ConvDOX). The study was performed using Wistar Han rats of both sexes that were treated intravenously for 28 days with 5 doses of tested substances at intervals of 5 days...
April 23, 2024: Nanoscale